Influenza

RNA vaccine
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

mRNA vaccine produces more diversified antibody response

A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels.   By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses.  … Read More

#News

Flu vaccine
#GSK #Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

GSK reveals plans to advance mRNA flu vaccine to Phase III

GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines.  The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More

#News

Influenza
#FDA #Influenza #OTC drugs #Reckitt

FDA approves first new OTC drug for cold and flu in 14 years

Reckitt’s Mucinex 12HR Cold & Fever Multi-Symptom is the first US Food and Drug Administration (FDA)-approved over-the-counter (OTC) drug in the cold and flu category in 14 years.  Mucinex that treats fever, cough, chest congestion and body pain for 12 hours.  According to The Centers for Disease Control and Prevention… Read More

#News #Regulatory

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step forward in global… Read More

#Business & Investment #News

Flu virus
#Antivirals #Biologics / Biotechnology #Cidara #Influenza #Merck #Mergers and acquisitions

Merck acquires antivirals developer Cidara Therapeutics

Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion.  Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to prevent influenza… Read More

#Business & Investment #News

Influenza
#Cidara #Clinical trial #Influenza

Phase III trial of flu preventative CD388 accelerated  

The Phase III study of CD388, a non-vaccine preventative of seasonal flu, has been accelerated by six months, biotechnology company Cidara Therapeutics has announced.  The planned Phase III study will be a global, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single… Read More

#News

Close up of vaccine syringe
#Covid-19 #Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #Moderna

Combination vaccine better than separate flu and Covid-19 jabs

In clinical trials, Moderna’s combination vaccine elicited higher immune responses against influenza (flu) virus and SARS-CoV-2 than licensed flu and Covid-19 vaccines in adults 50 years and older. The Phase III trial investigated mRNA-1083, an investigational combination vaccine against influenza and Covid-19. mRNA-1083 comprises… Read More

#News #Trending News

Antibodies
#Antibodies #Flu #Flu vaccine #Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH)

Novel antibodies target ‘dark side’ of influenza virus protein

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many… Read More

#Editor's Choice #News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

New DDW Highlights podcast: 22 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With seasonal illnesses running amok in the western hemisphere at the moment, it is… Read More

#News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

This week in drug discovery (15-19 January) 

News round-up for 15-19 January by DDW Digital Content Editor Diana Spencer. With seasonal illnesses running amok in the western hemisphere at the moment, it is perhaps not surprising that this week’s news highlights focus on viruses and immunity. The top stories: Antibody… Read More

#News

Older adult receiving vaccine
#Covid-19 #Immunity #Immunology / Virology & Vaccines #Influenza #University of Oxford

Collaborative study to improve flu and Covid-19 vaccine design

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most… Read More

#News

Doctor administering a vaccine to patient
#Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #University of Oxford

Oxford study to allow tailoring of Covid-19 and flu vaccines

The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. This study, funded by the Medical Research Council, will test the responses of cells… Read More

#News

Influenza
#Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH) #Phase I trial

Nanoparticle universal flu vaccine enters Phase I trials

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH,… Read More

#News

Cruciferous vegetables
#Endothelial dysfunction #Francis Crick Institute #Influenza #Virology

Could molecules in vegetables protect against lung infection?

Researchers at the Francis Crick Institute in the UK have found that molecules in vegetables like broccoli or cauliflower help to maintain a healthy barrier in the lung and ease infection. The aryl hydrocarbon receptor (AHR) is a protein found at barrier sites like the gut… Read More

#News

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

New DDW Highlights podcast: 10 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial… Read More

#News

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

This week in drug discovery (3-7 July)  

News round-up for 3-7 July by DDW Digital Content Editor Diana Spencer. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial of datopotamab deruxtecan did not meet its second primary endpoint and saw an 8% drop in its stock… Read More

#News